# Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
Canonical URL: https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-march-31-2026
Ticker: ENTA
Company: Enanta Pharmaceuticals
Source: Enanta Pharmaceuticals
Published: 2026-05-11 20:01 EST
Original Source URL: https://ir.enanta.com
## Summary

Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026 Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus

## Article Body
Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026 Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus
## Recent Company News
- 2026-05-28 11:00 EST — [Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference) — Source: Enanta Pharmaceuticals
- 2026-05-11 20:01 EST — [Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-ended-march-31-2026) — Source: Enanta Pharmaceuticals
- 2026-05-04 11:00 EST — [Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-data-for-its-respiratory-syncytial-virus-and-stat6-inhibitor-programs-at-the-american-thoracic-society-international-conference-2026) — Source: Enanta Pharmaceuticals
- 2026-04-13 11:00 EST — [Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-announces-first-participant-dosed-in-phase-1-clinical-trial-of-edp-978-an-oral-once-daily-kit-inhibitor-in-development-for-the-treatment-of-urticaria) — Source: Enanta Pharmaceuticals
- 2026-04-07 11:00 EST — [Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026](https://biopharmsignal.com/news/ENTA/enanta-pharmaceuticals-to-present-data-for-zelicapavir-an-oral-once-daily-n-protein-inhibitor-in-development-for-the-treatment-of-respiratory-syncytial-virus-at-escmid-global-2026) — Source: Enanta Pharmaceuticals
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)